1.
Clin Transl Radiat Oncol
; 25: 61-66, 2020 Nov.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33072895
RESUMO
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for 'gold standard' treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding.